Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00467-015-3104-8 http://scihub22266oqcxt.onion/10.1007/s00467-015-3104-8 C4646734!4646734!25980469     free     free     free       Pediatr+Nephrol 2016 ; 31 (3): 381-91 Nephropedia Template TP {{tp|p=25980469|t=2016. Biomarkers and surrogate endpoints in kidney disease |pdf=|usr=}}{{25980469}} gab.com Text Biomarkers and surrogate endpoints in kidney disease JO: Pediatr Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=25980469 #FOAvip Kidney disease and its related comorbidities impose a large public health burden. Despite this, the number of clinical trials in nephrology lags behind many other fields. An important factor contributing to the relatively slow pace of nephrology trials is that existing clinical endpoints have significant limitations. ?Hard? endpoints for chronic kidney disease, such as progression to end-stage renal disease, may not be reached for decades. Traditional biomarkers, such as serum creatinine in acute kidney injury, may lack sensitivity and predictive value. Finding new biomarkers to serve as surrogate endpoints is therefore an important priority in kidney disease research and may help to accelerate nephrology clinical trials. In this paper, I first review key concepts related to the selection of clinical trial endpoints and discuss statistical and regulatory considerations related to the evaluation of biomarkers as surrogate endpoints. This is followed by a discussion of the challenges and opportunities in developing novel biomarkers and surrogate endpoints in three major areas of nephrology research: acute kidney injury, chronic kidney disease, and autosomal dominant polycystic kidney disease. Twit Text FOAVip Biomarkers and surrogate endpoints in kidney disease ????Pediatr Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=25980469 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25980469 #FOAvip English Wikipedia <ref>{{Cite pmid|25980469}}</ref> Biomarkers and surrogate endpoints in kidney disease #MMPMID25980469 Hartung EA Pediatr Nephrol 2016[Mar]; 31 (3): 381-91 PMID25980469show ga Kidney disease and its related comorbidities impose a large public health burden. Despite this, the number of clinical trials in nephrology lags behind many other fields. An important factor contributing to the relatively slow pace of nephrology trials is that existing clinical endpoints have significant limitations. ?Hard? endpoints for chronic kidney disease, such as progression to end-stage renal disease, may not be reached for decades. Traditional biomarkers, such as serum creatinine in acute kidney injury, may lack sensitivity and predictive value. Finding new biomarkers to serve as surrogate endpoints is therefore an important priority in kidney disease research and may help to accelerate nephrology clinical trials. In this paper, I first review key concepts related to the selection of clinical trial endpoints and discuss statistical and regulatory considerations related to the evaluation of biomarkers as surrogate endpoints. This is followed by a discussion of the challenges and opportunities in developing novel biomarkers and surrogate endpoints in three major areas of nephrology research: acute kidney injury, chronic kidney disease, and autosomal dominant polycystic kidney disease. äBiomarkers and surrogate endpoints in kidney disease (epmc).pdf DeepDyve Pubget Overpricing